Genmab A (GMAB) Current Deferred Revenue (2020 - 2026)

Genmab A (GMAB) has reported Current Deferred Revenue for 7 consecutive years, with $88.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue rose 31.34% year-over-year to $88.0 million; the trailing twelve-month figure through Jun 2026 stood at $88.0 million (up 31.34% YoY), and the FY2025 full-year result was $95.0 million, up 41.79% from the prior year.
• Current Deferred Revenue was little changed at $88.0 million in Q2 2026 per GMAB's latest filing, from $88.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $95.0 million in Q4 2025 and bottomed at $3.1 million in Q4 2024.
• Historically, Current Deferred Revenue has averaged $55.6 million across 5 years, with a median of $46.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue slumped 93.19% in 2024, then jumped 2994.06% in 2025.
• Over 5 years, Current Deferred Revenue stood at $44.8 million in 2022, then increased by 0.67% to $45.1 million in 2023, then sank by 93.19% to $3.1 million in 2024, then surged by 2994.06% to $95.0 million in 2025, then declined by 7.37% to $88.0 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $88.0 million, $88.0 million, and $95.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.